Nelarabine Patent Expiration
Nelarabine is used for treating T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma that have not responded to or relapsed after two chemotherapy regimens. It was first introduced by Sandoz Inc
Nelarabine Patents
Given below is the list of patents protecting Nelarabine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Arranon | US5424295 | 9-β-D-arabinofuranasyl-2-amino-6-methaoxy-9H-purine |
Jun 13, 2017
(Expired) | Sandoz |
| Arranon | US5492897 | Method for treating T-cell lymphoblastic leukemia with ara-G nucleoside derivatives |
Feb 20, 2013
(Expired) | Sandoz |
| Arranon | US5747472 | Therapeutic methods for using ARA-G derivatives |
Feb 20, 2013
(Expired) | Sandoz |
| Arranon | US5821236 | Tumor treatment with arabinofuranosyl purine derivatives |
Feb 20, 2013
(Expired) | Sandoz |
Nelarabine's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List